Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3101 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 29 30 31 32  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Amal Therapeutics–VI Partners: investment, 201603 financing round Series A totalling CHF3m incl co-investor VI Partners 2016-03-30
BioChain–Epigenomics: molecular diagnostics, 201603– license excl blood-based lung cancer test for developm + commercialisation in China 2016-03-30
Zavante Therapeutics–SEVERAL: investment, 201603 financing round Series A $45m with $35m from new investors + $10m conversion of convertible notes 2016-03-30
Exiqon–Qiagen: investment, 201603–201606 conditional voluntary takeover offer DKK683m ($100m) 2016-03-29
Gadeta–SEVERAL: investment, 201603 financing round Series A €7m led by Medicxi Ventures + Baxalta Ventures with Utrecht Holdings + founders + managers 2016-03-29
ABBA Therapeutics–Ligand: transgenic animal technology, 201603– license to use OmniAb platform to develop MAbs + bi-specific ABs 2016-03-28
Bayer–Holta Invest: investment, 201603 existent Bayer listed as portfolio company of Holta Life Sciences 2016-03-28
Roche–Holta Invest: investment, 201603 existent Roche listed as portfolio company of Holta Life Sciences 2016-03-28
Diatron–Stratec: investment, 201603 acquisition 100% of Diatron MI PLC by Stratec from The Riverside Company 2016-03-23
Padlock Therapeutics–BMS: investment, 201603–201604 acquisition 100% for up to $600m 2016-03-23
Thuringia (govt)–High-Tech Gründerfonds: venture capital, 201603– collab renewed TSF + HTGF to jointly provide up to €3.15m for early financings 2016-03-23
Topas Therapeutics–EMBL: investment, 201603 financing round Series A totalling €14m incl co-investor EMBL Ventures 2016-03-22
Topas Therapeutics–Epidarex Capital: investment, 201603 financing round Series A totalling €14m led by Epidarex 2016-03-22
Topas Therapeutics–Evotec: investment, 201603 financing round Series A totalling €14m incl co-investor Evotec AG 2016-03-22
Topas Therapeutics–Gimv: investment, 201603 financing round Series A totalling €14m incl €4m from co-investor Gimv Health & Care 2016-03-22
Topas Therapeutics–SEVERAL: investment, 201603 financing round Series A €14m led by Epidarex incl EMBL Ventures + Gimv + Evotec 2016-03-22
GSK–Miltenyi Biotec: cell/gene therapy, 201603– collab cell + gene therapy incl CAR-T using increased automation 2016-03-16
SkyePharma–Vectura: investment, 201603– acquisition merger £441m in shares (up to £70m cash) resulting in 41.75% (37.62%) for former Skye owners 2016-03-16
Almirall–Grünenthal: investment, 201603– acquisition 100% of Almirall de Mexico SA de CV by Grünenthal ANNNOUNCED 2016-03-15
Bohui–Univ Freiburg: mass spec sample introduction technique, –201603 collab developm iASAP Prof Krossing + license of patent rights to Advion 2016-03-15
Roche–Blueprint Medicines: kinase inhibitors, 201603– collab ww $45m upfront + $965m milestones r+d + commerc up to 5 small molelcule drugs 2016-03-15
eTheRNA–Boehringer: investment, 201603 financing round Series A totalling €24m incl co-investor BIVF 2016-03-14
eTheRNA–Flanders (govt): investment, 201603 financing round Series A totalling €24m led by PMV + Life Sciences Partners 2016-03-14
eTheRNA–Fund+: investment, 201603 financing round Series A totalling €24m incl co-investor Fund+ 2016-03-14
eTheRNA–Life Sciences Partners: investment, 201603 financing round Series A totalling €24m led by Life Sciences Partners + PMV 2016-03-14
eTheRNA–Omega Funds: investment, 201603 financing round Series A totalling €24m incl co-investor Omega Funds 2016-03-14
eTheRNA–SEVERAL: investment, 201603 financing round Series A €24m led by Life Sciences Partners + PMV 2016-03-14
Agilent–Eurofins: genomic technology, 201603– collab Eurofins Genomics supplies custom components for Agilent’s SureVector cloning kits 2016-03-10
Aprea–MC Services: public relations, 201602 service existent for Aprea AB 2016-03-09
AbbVie–Boehringer: therap antibodies, 201603– collab + acqu ww rights BI 655066 + BI 655064 for $595m upfront + undisclosed milestones + royalties 2016-03-07
Argos–SEVERAL: investment, 201603– securities purchase agreem up to $60m common stock + warrants in 3 tranches incl Pharmstandard + TVM 2016-03-07
ITM Isotopen Technologien München–OTHER: investment, 201603 equity investment €20m from Medtech-focused family office 2016-03-07
Biocom–Nasdaq OMX: press release distribution, 201603 collab existent integration of channel news in Eurobiotechnews.eu portal 2016-03-06
Snowy Range Instruments–Metrohm: investment, 201603 acquisition of majority by Metrohm + SnRI renamed Metrohm Raman 2016-03-04
Biolink (NO)–Evonik: investment, 201603 acquisition €na of MedPalett AS by Evonik from Biolink Group 2016-03-03
Grünenthal–Axxam: drug discovery services, 201603– collab to discover small moleucule lead structures to treat pain + inflammation 2016-03-03
Pulsar Photonics–High-Tech Gründerfonds: investment, 201603 seed financing from HTGF 2016-03-02
Cycle GmbH–Hamburg (govt): investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode 2016-03-01
Cycle GmbH–High-Tech Gründerfonds: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode 2016-03-01
Cycle GmbH–PERSON: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode 2016-03-01
Cycle GmbH–SEVERAL: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode 2016-03-01
Merck (DE)–EMBL: drug discovery, 201603–201902 collab research 3y with EMBL Heidelberg w focus on cancer metabolism 2016-03-01
Retina Implant–SEVERAL: investment, 201602 private equity funding round €26m from existing + new investors 2016-02-29
CPGR (ZA)–Thermo Fisher: mass spectrometer, 201602 supply existent Q Exactive MS system used for proteomics 2016-02-26
Blue Scientific–Accurion: laboratory instruments, 201602– distribution Nanofilm Technology + Halcyonics products in UK + Nordics by Blue Scientific 2016-02-25
Transcend Medical–Novartis: investment, 201602 acquisition €na by Alcon 2016-02-18
Saphetor–Capricorn One: public relations, 201602 service existent for Saphetor SA 2016-02-17
Saphetor–SEVERAL: investment, 201602 seed financing round CHF1.2m from undisclosed investors 2016-02-17
Venture Valuation–Nasdaq OMX: press release distribution, 201602– collab integration of channel news in Biotechgate online directories 2016-02-17
Apogenix–Germany (govt): grant, 201602 BMBF grant €3m for developm of companion diagnostic w R-Biopharm for APG101 in glioblastoma 2016-02-16
Novartis–Pfizer: biosimilar, 201602– Sandoz acquires rights to PF-06438179 (infliximab) in EEA which Pfizer had to divest after Hospira acquisition 2016-02-12
Curetis–Degroof Petercam: financial services, 201602– supply service liquidity provider to facilitate share trading on Euronext Brussels + Amsterdam 2016-02-11
Hemovent–SEVERAL: investment, 201602 financing round Series A $6m led by MIG Verwaltungs AG 2016-02-10
Qiagen–10x Genomics: genomic technology, 201602– collab co-developm + co-marketing of NGS + single-cell biology + bioinformatics solutions 2016-02-09
SmartDyeLivery–SEVERAL: investment, 201602 seed financing from bm|t + Sparkasse Jena-Saale-Holzland 2016-02-03
Evotec–Michael J Fox Foundation: grant, 201602 research grant for further developm of TargetaSN programme to treat Parkinson’s disease 2016-02-02
Mission Therapeutics–Roche: investment, 201602 financing round totalling £60m incl returning co-investor Roche Venture Fund 2016-02-02
PharmGenomics (DE)–SEVERAL: investment, 201601 financing round incl ISB + KfW + private investors 2016-01-20
Novartis–Surface Oncology: cancer immunotherapy, 201601– collab + license up to $170m in upfront + equity + milestones for 4 pre-clinical programs 2016-01-11
Novimmune–SEVERAL: investment, 201601 financing round CHF30m from existing shareholders 2016-01-11
Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix 2016-01-07
C4 Therapeutics–Roche: investment, 201601 financing round Series A totalling $73m incl lead investor Cobro Ventures + co-investor Roche 2016-01-07
C4 Therapeutics–SEVERAL: investment, 201601 financing round Series A $73m led by Cobro plus Cormorant + Kraft Group + EG Capital + Roche + Novartis 2016-01-07
Roche–C4 Therapeutics: drug discovery, 201601– collab up to >750m developm TPD therapeutics against Roche targets using Degronimid platform 2016-01-07
Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG 2016-01-01
MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems 2016-01-01
Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program 2016-01-01
Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets 2016-01-01
Mologen–Bâloise: investment, 201512 existing investor Bâloise Holding holding estimated 6% in Mologen 2015-12-31
Mologen–Deutsche Balaton: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Global Derivative Trading: investment, 201512 existing investor Global Derivative Trading GmbH owns estimated 24% in Mologen 2015-12-31
Mologen–Salvator Vermögensverwaltungs GmbH: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Signal Iduna: investment, 201512 existing investor Deutscher Ring Krankenversicherung holding estimated 6% in Mologen 2015-12-31
Boehringer–Polyphor: drug discovery, 201512 collab existent to identify + optimise drug candidates using macrocycle platform 2015-12-22
Complix–Selexis: biological contract manufacturing, 201512– supply SUREtechnology platform to enable production of Alphabody candidate CMX-02 2015-12-14
NovaPump–SEVERAL: investment, 201512 financing round with bm|t + Sparkasse Jena-Saale-Holzland 2015-12-14
Basilea–SEVERAL: credit, 201512 senior unsecured convertible bonds CHF200m with coupon of 2.75% per annum due 2022 2015-12-09
Convergence Pharmaceuticals–Evotec: investment, 201512 acquisition of 51% of shares of Panion Ltd 2015-12-09
Bridgepoint–Kohlberg Kravis Roberts: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint 2015-12-08
Cypher Genomics–Human Longevity: investment, 201511 acquisition €na of Cypher Genomics by HLI 2015-11-30
TiGenix–Cormorant Asset Management: investment, 201511 private placement totalling €8.7m incl €4.7m to Cormorant Global Healthcare 2015-11-25
TiGenix–SEVERAL: investment, 201511 private placement €8.7m with 9.1m new shares €0.95/share to Cormorant + European institutional investors 2015-11-25
Merck (DE)–Univ Cape Town: malaria drug, 201511– collab research with UCT H3D to develop anti-malarial drug candidates using Merck compound library 2015-11-19
Greiner–Oncgnostics: cervical cancer test, 201511– distribution of GynTect test by Greiner Bio-One in DACH + FR + GB + Benelux 2015-11-18
Oncotest–Charles River: investment, 201511 acquisition of Oncotest GmbH for €34m in cash + €2m milestones 2015-11-18
Nestlé–ImaBiotech: mass spectrometry services, 201511– supply Multimaging services for Galderma’s drug development 2015-11-10
Syngenta–DSM: microbial agricultural solutions, 201511– collab developm microbial-based solutions incl bio-controls + bio-pesticides + bio-stimulants 2015-11-06
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m 2015-11-02
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund 2015-11-01
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m 2015-11-01
Co.don–SEVERAL: investment, 201510–201511 capital increase €5m with 2.5m new shares at €2/share w existing + new investors 2015-10-30
GeneWake–R-Biopharm: investment, 201510 acquisition of GeneWake GmbH which had filed for bankruptcy in February 2015 2015-10-29
Agena Bioscience–Diatech: mass spec-based MDx, 201510– collab developm MassARRAY genomic CDx tests for cancer therapy w Diatech Pharmacogenetics Srl 2015-10-27
Biofrontera–SEVERAL: investment, 201510–201511 capital increase €3.64m net €3.1m with 1.92m new shares at €2/share 2015-10-27
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management 2015-10-21
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
next pagenext page 1 2 3 ... 29 30 31 32  next pagenext page



Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BIO-Europe Spring 2021 Digital 650x80

» top